Combination treatment for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread, returned, or persists
- The cancer cannot be cured with surgery or radiation
- You are at least 18 years old and able to take part in study visits
- Your cancer type is squamous cell, adenosquamous, or adenocarcinoma
- You have not had chemotherapy before (except with radiation at the same time)
- You have not had previous immunotherapy treatment
- Your organs and bone marrow are functioning well enough (blood tests will check this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.